Full Description
DNA Repair and Cancer Therapy: Molecular Targets and Clinical Applications, Second Edition provides a comprehensive and timely reference that focuses on the translational and clinical use of DNA repair as a target area for the development of diagnostic biomarkers and the enhancement of cancer treatment.
Experts on DNA repair proteins from all areas of cancer biology research take readers from bench research to new therapeutic approaches. This book provides a detailed discussion of combination therapies, in other words, how the inhibition of repair pathways can be coupled with chemotherapy, radiation, or DNA damaging drugs.
Newer areas in this edition include the role of DNA repair in chemotherapy induced peripheral neuropathy, radiation DNA damage, Fanconi anemia cross-link repair, translesion DNA polymerases, BRCA1-BRCA2 pathway for HR and synthetic lethality, and mechanisms of resistance to clinical PARP inhibitors.
Contents
1. Overview of Current Targets and Clinical Trials: Bench to Clinic2. MGMT a Critical DNA Repair Gene Target for Chemotherapy Resistance3. Blockade of Base Excision Repair: Inhibition of Small Lesions Results in Big Consequences to Cancer Cells4. PARP Inhibitors - Scientific Rationale and Clinical Development for Cancer5. Inhibiting Selective DNA Polymerases for Therapeutic Intervention6. Targeting the Nucleotide Excision Repair Pathway for Therapeutic Applications7. Homologous Recombination and ATM/ATR Targets8. DNA Double Strand Break Repair by Nonhomologous End Joining and its Clinical Relevance9. Mismatch repair10. DNA Repair Signaling Targets11. Personalized Cancer Medicine: DNA Repair Alterations is a Promising Predictive Marker in Cancer12. The Role of DNA Damage and Repair in Neurotoxicity Caused by Cancer Therapies13. Radiation DNA damage and use in cancer/therapeutics/dna repair14. Fanconi Anemia- cross-link repair15. Translesion DNA polymerases16. BRCA1-BRCA2 pathway for HR and synthetic lethality17. Synthetic lethality18. Mechanisms of Resistance to Clinical PARP Inhibitors
